Cargando…
Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6
In this study, we present efavirenz physiologically based pharmacokinetic (PBPK) model development as an example of our best practice approach that uses a stepwise approach to verify the different components of the model. First, a PBPK model for efavirenz incorporating in vitro and clinical pharmaco...
Autores principales: | Ke, A, Barter, Z, Rowland‐Yeo, K, Almond, L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961080/ https://www.ncbi.nlm.nih.gov/pubmed/27435752 http://dx.doi.org/10.1002/psp4.12088 |
Ejemplares similares
-
Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling
por: Rowland Yeo, Karen, et al.
Publicado: (2020) -
A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction
por: Ke, A B, et al.
Publicado: (2012) -
Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz
por: Chetty, Manoranjenni, et al.
Publicado: (2018) -
Development and application of a PBPK modeling strategy to support antimalarial drug development
por: Abla, Nada, et al.
Publicado: (2023) -
PBPK modeling to predict drug‐drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction
por: Bolleddula, Jayaprakasam, et al.
Publicado: (2021)